Publications by authors named "Jean-Louis Legoux"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

333

Total Likes

16

Extended Reach

41,420

Social Features

13
N
Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial.
Mélissa Gruner, Angélique Denis, Claude Masliah, Morgane Amil, Elodie Metivier-Cesbron, Dominique Luet, Medhi Kaasis, Emmanuel Coron, Marc Le Rhun, Stéphane Lecleire

Endoscopy· July 2021

Videos about Article: user

1 2 12

View All Article and Social Media Activity
C
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Emeric Boisteau, Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jérôme Desramé, Jean-Louis Legoux

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.
Elodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel, François Bocquet, Olivier Bouché, Jean-Louis Legoux

Curr Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron

Cancers (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study.
Aziz Zaanan, Julie Henriques, Anthony Turpin, Sylvain Manfredi, Romain Coriat, Jean-Louis Legoux

JNCI Cancer Spectr· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Côme Lepage, Jean-Marc Phelip, Astrid Lievre, Karine Le-Malicot, Laetitia Dahan, Jean-Louis Legoux

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
Claire Gallois, Jean-François Emile, Stefano Kim, Carole Monterymard, Marine Gilabert, Jean-Louis Legoux

Dig Liver Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.
Jean-Louis Legoux, Catherine Lombard-Bohas, Hedia Brixi, Karine Le Malicot, Thierry Lecomte

Clin Res Hepatol Gastroenterol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study.
Alexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, Astrid Pozet, David Tougeron, Jean-Louis Legoux

Clin Res Hepatol Gastroenterol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.
Clémence Breton, Thomas Aparicio, Karine Le Malicot, Michel Ducreux, Thierry Lecomte, Jean-Louis Legoux

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Mehdi Karoui, Claire Gallois, Guillaume Piessen, Jean-Louis Legoux, Emilie Barbier

Colorectal Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
Thomas Aparicio, Magali Svrcek, Julie Henriques, Pauline Afchain, Astrid Lièvre, Jean-Louis Legoux

Int J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Sylvain Manfredi, Anthony Turpin, David Malka, Emilie Barbier, Pierre Laurent-Puig, Jean-Louis Legoux

Dig Liver Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.
Thomas Aparicio, Julie Henriques, Sylvain Manfredi, David Tougeron, Olivier Bouché, Jean-Louis Legoux

Int J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Julie Niogret, Emeric Limagne, Marion Thibaudin, Julie Blanc, Aurelie Bertaut, Jean-Louis Legoux

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Louis de Mestier, Thomas Walter, Hedia Brixi, Camille Evrard, Jean-Louis Legoux

Neuroendocrinology· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
Thomas Walter, Come Lepage, Romain Coriat, Emilie Barbier, Guillaume Cadiot, Jean-Louis Legoux

Eur J Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jean-Louis Jouve, Thierry Lecomte, Olivier Bouché, Emilie Barbier, Faiza Khemissa Akouz, Jean-Louis Legoux

J Hepatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, Karine Le Malicot, Jean-François Seitz, Jean-Louis Legoux

Bull Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.
Pierre Rompteaux, Johan Gagnière, Jean-Marc Gornet, Romain Coriat, Isabelle Baumgaertner, Jean-Louis Legoux

Eur J Surg Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, Guillaume Cadiot, Sophie Dominguez, Jean-Louis Legoux

Neuroendocrinology· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Thierry Conroy, Pascal Hammel, Mohamed Hebbar, Meher Ben Abdelghani, Alice C Wei, Jean-Louis Legoux

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Thomas Aparicio, Michel Ducreux, Roger Faroux, Emilie Barbier, Sylvain Manfredi, Jean-Louis Legoux

Eur J Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Côme Lepage, Laetitia Dahan, Nadia Bouarioua, Christos Toumpanakis, Jean-Louis Legoux

Dig Liver Dis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).
Jean-Pierre Gérard, Thierry André, Frédéric Bibeau, Thierry Conroy, Jean-Louis Legoux

Dig Liver Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis